Clinical Trials Archive

A building with a stone facade displays a sign that reads
Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release
A building with a stone facade displays a sign that reads
Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma
A building with a stone facade displays a sign that reads
IBTC Data and Tissue Screening Protocol
A building with a stone facade displays a sign that reads
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
A building with a stone facade displays a sign that reads
DEFIANCE – ClotTriever® Thrombectomy System vs. Anticoagulation Alone for Treatment of Deep Vein Thrombosis
A building with a stone facade displays a sign that reads
Assessment of Implantable CCM in the Heart Failure Group With Higher Ejection Fraction
A building with a stone facade displays a sign that reads
A Phase 2b, Multicenter, Double-blind, Placebo-controlled Randomized Withdrawal Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat, ACPA-Positive Rheumatoid Arthritis
A building with a stone facade displays a sign that reads
Rollover Study to Continue IMSA101 Treatments in Patients With Advanced Treatment-Refractory Malignancies Previously Enrolled in the Phase I/IIA Safety and Efficacy Study of IMSA101
A building with a stone facade displays a sign that reads
A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator’s Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)
A building with a stone facade displays a sign that reads
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma